AbbVie Inc Dossier

AbbVie Inc reported total net revenues of $60.5 billion and an operating income of $27.2 billion for the fiscal year 2025, supported by sustained commercial momentum across its diversified therapeutic portfolios.

Financial Highlights

* Total Net Revenue: $60.5 billion

* Operating Income: $27.2 billion

* Adjusted Diluted EPS: $11.98

* Adjusted Gross Margin: 84%

* Adjusted Operating Margin: 45%

* Research and Development Expense: $9.0 billion

* Operating Cash Flow: $19.28 billion

* Dividend Yield: 2.87%

Strategic Analysis

AbbVie Inc has effectively navigated a critical pivot point in its corporate history during fiscal year 2025, demonstrating the durability of its diversified portfolio. The primary driver of this resilience is the robust commercial performance of the immunology segment, where the combined trajectory of Skyrizi and Rinvoq is on track to surpass $17 billion in sales, effectively counterbalancing the impact of biosimilar competition on Humira revenues. Concurrently, the neuroscience division has emerged as a significant growth... Sign in / Sign up to learn more about AbbVie Inc

Continue your research by chatting with our AI financial analyst about AbbVie Inc. Ask follow-up questions, request specific analysis, or explore investment scenarios. All insights are grounded in verified financial data and SEC filings.

Start your analysis with these investor-focused questions:

• Given the divergent performance in FY2025 with strong growth in Neuroscience (+24.2% YoY) and Immunology (+9.5% YoY) contrasting with declines in the Aesthetics (-8.1% YoY) and Eye Care (-3.9% YoY) segments, how does this shift in revenue mix impact AbbVie Inc.'s overall margin profile and long-term growth strategy?
• AbbVie Inc.'s core strategy relies on its Immunology portfolio, specifically Skyrizi and Rinvoq, to offset the revenue erosion from Humira. Based on the FY2025 outlook, how can we evaluate the success of this transition and what are the key risks to these products meeting their growth expectations?
• With a total debt of approximately $70.6 billion and a current ratio of 0.74 as of June 2025, what are the primary risks associated with AbbVie Inc.'s capital structure, and how might this leverage impact its capacity for future strategic acquisitions and shareholder returns?
• AbbVie Inc. is projected to spend $9 billion on R&D in FY2025 and has been highly active in business development. How does the acquisition of Cerevel Therapeutics and the focus on platforms like in-vivo CAR-T position AbbVie Inc.'s Neuroscience and Immunology pipelines for future growth beyond the current blockbusters?
• Considering the reported negative book value per share (-$0.10) and an extremely high Return on Equity (112.85%), what does this combination suggest about AbbVie Inc.'s financial structure and use of leverage, and what are the implications for an investor's assessment of the company's intrinsic value?